By Maria Armental 
 

Novartis AG said its cancer drug Kymriah showed consistent efficacy and safety outcomes when used in real-world settings on a broader group of U.S. patients.

The analyses are from a readout of a 15-year post-marketing study looking at Kymriah in adults with relapsed or refractory diffuse large B cell lymphoma, the most common type of lymphoma, and in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

Kymriah (tisagenlecleucel), which company officials expect to reach blockbuster potential over the next five years, is part of a type of therapies known as Car-T that use genetically engineered T-cells to attack the blood cancer.

 

Write to Maria Armental at maria.armental@wsj.com

 

(END) Dow Jones Newswires

December 09, 2019 16:15 ET (21:15 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Novartis Charts.